Zhenliang Hao , Xuewei Zhang , Ning Yao , Kai Li , Luxin Lou , Xuan Zheng , Zhiming Guo , Jiabin Chen , Xuzhu Chen
{"title":"轴状和尾状骨骼血管肉瘤的临床病理特征和生存差异:基于seer的竞争风险模型分析","authors":"Zhenliang Hao , Xuewei Zhang , Ning Yao , Kai Li , Luxin Lou , Xuan Zheng , Zhiming Guo , Jiabin Chen , Xuzhu Chen","doi":"10.1016/j.jbo.2026.100740","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div> <!-->Primary angiosarcoma of bone (ASB) is a rare and aggressive primary bone tumor. The prognostic significance of anatomical location (axial vs. appendicular skeleton) remains poorly defined. This study aimed to compare clinicopathological features and survival outcomes between these two groups.</div></div><div><h3>Methods</h3><div> <!-->Patients diagnosed with primary ASB (1975–2019) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Tumors were categorized as axial (spine, pelvis, ribs, skull) or appendicular (extremities). Overall survival was analyzed using Kaplan-Meier and Cox models. Cancer-specific mortality (CSM) was evaluated with Fine-Gray competing risk regression to calculate subdistribution hazard ratios (SHR).</div></div><div><h3>Results</h3><div> <!-->Among 458 patients, 162 (35.4%) had axial and 296 (64.6%) had appendicular tumors. Axial patients were older (median 63 vs. 46 years, p < 0.001), had higher distant metastasis at diagnosis (43.2% vs. 29.1%, p = 0.002), and underwent surgery less frequently (37.0% vs. 81.1%, p < 0.001). The 5-year overall survival was significantly worse for axial tumors (16.8% vs. 38.2%, p < 0.001). The 5-year cumulative incidence of CSM was 69.5% for axial versus 50.8% for appendicular tumors (p < 0.001). Multivariate analysis confirmed axial location as an independent predictor of higher CSM (SHR 1.62, 95% CI: 1.25–2.10, p < 0.001) ,<!--> <!-->independent of the year of diagnosis.</div></div><div><h3>Conclusions</h3><div>Axial tumors represent a distinct high-risk subgroup characterized by limited surgical resectability and inferior survival. Anatomical location should be considered a critical stratification factor in clinical management and future trials.</div><div>Abbreviations: <strong>ASB,</strong> Primary angiosarcoma of the bone; <strong>SEER,</strong> Surveillance, Epidemiology, and End Results; <strong>OS,</strong> Overall Survival; <strong>CSS,</strong> Cancer-Specific Survival; <strong>CSD,</strong> Cancer-Specific Death; <strong>CIF,</strong> Cumulative Incidence Function; <strong>SHR,</strong> Subdistribution Hazard Ratio; <strong>CI,</strong> Confidence Interval; <strong>HR,</strong> Hazard Ratio.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"57 ","pages":"Article 100740"},"PeriodicalIF":3.5000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinicopathological features and survival disparities between axial and appendicular skeletal Angiosarcoma: A SEER-based analysis using competing risk models\",\"authors\":\"Zhenliang Hao , Xuewei Zhang , Ning Yao , Kai Li , Luxin Lou , Xuan Zheng , Zhiming Guo , Jiabin Chen , Xuzhu Chen\",\"doi\":\"10.1016/j.jbo.2026.100740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div> <!-->Primary angiosarcoma of bone (ASB) is a rare and aggressive primary bone tumor. The prognostic significance of anatomical location (axial vs. appendicular skeleton) remains poorly defined. This study aimed to compare clinicopathological features and survival outcomes between these two groups.</div></div><div><h3>Methods</h3><div> <!-->Patients diagnosed with primary ASB (1975–2019) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Tumors were categorized as axial (spine, pelvis, ribs, skull) or appendicular (extremities). Overall survival was analyzed using Kaplan-Meier and Cox models. Cancer-specific mortality (CSM) was evaluated with Fine-Gray competing risk regression to calculate subdistribution hazard ratios (SHR).</div></div><div><h3>Results</h3><div> <!-->Among 458 patients, 162 (35.4%) had axial and 296 (64.6%) had appendicular tumors. Axial patients were older (median 63 vs. 46 years, p < 0.001), had higher distant metastasis at diagnosis (43.2% vs. 29.1%, p = 0.002), and underwent surgery less frequently (37.0% vs. 81.1%, p < 0.001). The 5-year overall survival was significantly worse for axial tumors (16.8% vs. 38.2%, p < 0.001). The 5-year cumulative incidence of CSM was 69.5% for axial versus 50.8% for appendicular tumors (p < 0.001). Multivariate analysis confirmed axial location as an independent predictor of higher CSM (SHR 1.62, 95% CI: 1.25–2.10, p < 0.001) ,<!--> <!-->independent of the year of diagnosis.</div></div><div><h3>Conclusions</h3><div>Axial tumors represent a distinct high-risk subgroup characterized by limited surgical resectability and inferior survival. Anatomical location should be considered a critical stratification factor in clinical management and future trials.</div><div>Abbreviations: <strong>ASB,</strong> Primary angiosarcoma of the bone; <strong>SEER,</strong> Surveillance, Epidemiology, and End Results; <strong>OS,</strong> Overall Survival; <strong>CSS,</strong> Cancer-Specific Survival; <strong>CSD,</strong> Cancer-Specific Death; <strong>CIF,</strong> Cumulative Incidence Function; <strong>SHR,</strong> Subdistribution Hazard Ratio; <strong>CI,</strong> Confidence Interval; <strong>HR,</strong> Hazard Ratio.</div></div>\",\"PeriodicalId\":48806,\"journal\":{\"name\":\"Journal of Bone Oncology\",\"volume\":\"57 \",\"pages\":\"Article 100740\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2026-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bone Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212137426000023\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/1/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212137426000023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Clinicopathological features and survival disparities between axial and appendicular skeletal Angiosarcoma: A SEER-based analysis using competing risk models
Background
Primary angiosarcoma of bone (ASB) is a rare and aggressive primary bone tumor. The prognostic significance of anatomical location (axial vs. appendicular skeleton) remains poorly defined. This study aimed to compare clinicopathological features and survival outcomes between these two groups.
Methods
Patients diagnosed with primary ASB (1975–2019) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Tumors were categorized as axial (spine, pelvis, ribs, skull) or appendicular (extremities). Overall survival was analyzed using Kaplan-Meier and Cox models. Cancer-specific mortality (CSM) was evaluated with Fine-Gray competing risk regression to calculate subdistribution hazard ratios (SHR).
Results
Among 458 patients, 162 (35.4%) had axial and 296 (64.6%) had appendicular tumors. Axial patients were older (median 63 vs. 46 years, p < 0.001), had higher distant metastasis at diagnosis (43.2% vs. 29.1%, p = 0.002), and underwent surgery less frequently (37.0% vs. 81.1%, p < 0.001). The 5-year overall survival was significantly worse for axial tumors (16.8% vs. 38.2%, p < 0.001). The 5-year cumulative incidence of CSM was 69.5% for axial versus 50.8% for appendicular tumors (p < 0.001). Multivariate analysis confirmed axial location as an independent predictor of higher CSM (SHR 1.62, 95% CI: 1.25–2.10, p < 0.001) , independent of the year of diagnosis.
Conclusions
Axial tumors represent a distinct high-risk subgroup characterized by limited surgical resectability and inferior survival. Anatomical location should be considered a critical stratification factor in clinical management and future trials.
Abbreviations: ASB, Primary angiosarcoma of the bone; SEER, Surveillance, Epidemiology, and End Results; OS, Overall Survival; CSS, Cancer-Specific Survival; CSD, Cancer-Specific Death; CIF, Cumulative Incidence Function; SHR, Subdistribution Hazard Ratio; CI, Confidence Interval; HR, Hazard Ratio.
期刊介绍:
The Journal of Bone Oncology is a peer-reviewed international journal aimed at presenting basic, translational and clinical high-quality research related to bone and cancer.
As the first journal dedicated to cancer induced bone diseases, JBO welcomes original research articles, review articles, editorials and opinion pieces. Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject.
The areas covered by the journal include:
Bone metastases (pathophysiology, epidemiology, diagnostics, clinical features, prevention, treatment)
Preclinical models of metastasis
Bone microenvironment in cancer (stem cell, bone cell and cancer interactions)
Bone targeted therapy (pharmacology, therapeutic targets, drug development, clinical trials, side-effects, outcome research, health economics)
Cancer treatment induced bone loss (epidemiology, pathophysiology, prevention and management)
Bone imaging (clinical and animal, skeletal interventional radiology)
Bone biomarkers (clinical and translational applications)
Radiotherapy and radio-isotopes
Skeletal complications
Bone pain (mechanisms and management)
Orthopaedic cancer surgery
Primary bone tumours
Clinical guidelines
Multidisciplinary care
Keywords: bisphosphonate, bone, breast cancer, cancer, CTIBL, denosumab, metastasis, myeloma, osteoblast, osteoclast, osteooncology, osteo-oncology, prostate cancer, skeleton, tumour.